TAK

AI Memo

Takeda Pharmaceutical

As of 2026-01-30/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-30 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Next quarterly results (assumed window) • 2026-04-30

Base target: $17 / p=60% prob

Biggest risk

Bear case: Negative readouts, guidance misses, or regulatory setbacks push the stock toward the analyst low (14.87). FX headwinds, weaker launch uptake, or failure to deliver synergies would deepen the downside.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

Bull case: Successful clinical readouts, clearer post-quarter guidance, and tangible cost-synergy realization drive re-rating toward the analyst high (19.5). Stronger-than-expected launch execution or an accretive licensing/M&A outcome would add incremental upside.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-30

Base target

$17

p=60%

Bull target

$20

p=20%

Bear target

$15

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Analyst target revisions
Pipeline readouts and strategic execution
Bull case: Successful clinical readouts, clearer post-quarter guidance, and tangible cost-synergy realization drive re-rating toward the analyst high (19.5).

BearKey bullets

Failure to deliver integration synergies or cost savings
Major litigation or product-safety event
Material FX (JPY) translation headwinds

WatchKey bullets

Next quarterly results (assumed window)

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $17 (p=60%)

Target spread vs base: +15% / -13%

Scenario probabilities

Bull Target: $20 (p=20%)Base Target: $17 (p=60%)Bear Target: $15 (p=20%)

Commentary

Consensus targets cluster around the current price with a median near the mid-$16s and a high near $19.5, implying limited near-term upside from the anchor absent positive clinical or regulatory news. Market tone is neutral-to-cautious; upside is contingent on successful readouts, credible guidance, and execution on cost synergies.

As of 2026-01-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Analyst target revisions
Pipeline readouts and strategic execution

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-30Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$16.73

Range (USD)

$14.87 - $19.50

Count

Query: Takeda Pharmaceutical Co Ltd ADR (TAK) analyst consensus price target high low average

Takeda Pharmaceutical Co. Ltd. ADR Analyst Estimates - MarketWatch
Search result #1
Stock Price Targets. High, $19.50. Median, $17.11. Low, $14.87. Average, $16.87. Current Price, $16.91. Yearly Numbers. Estimates. TAK will report 2026 earnings ...
Extracted: $19.50, $17.11, $14.87, $16.87, $16.91Open source
Takeda Pharmaceutical Co Ltd ADR (TAK) Stock Forecast & Price ...
Search result #2
According to projections from 3 analysts, the average 12-month price target for Takeda Pharma ADR is 19.14, with a high estimate of 19.99712569 and a low ...
Open source
Takeda Pharmaceutical Co. Ltd. ADR Analyst Estimates & Ratings
Search result #3
Stock Price Target TAK. High, $19.50. Median, $16.29. Low, $14.87. Average, $16.59. Current Price, $16.29. Related Links: Options · Overview · Research & ...
Extracted: $19.50, $16.29, $14.87, $16.59Open source
Takeda Pharmaceutical Co. Ltd. ADR Research & Ratings - Barron's
Search result #4
Average price target from 14 ratings: $16.42. Average Score: Sell. Under. Hold ... Fundamental company data and analyst estimates provided by FactSet.
Extracted: $16.42Open source
Takeda Pharmaceutical Company Limited: Target Price Consensus ...
Search result #5
Mean consensus. OUTPERFORM ; Number of Analysts. 15 ; Last Close Price. 5,130.00JPY ; Average target price. 5,196.40JPY ; Spread / Average Target. +1.29%.
Open source
Takeda Pharmaceutical Company Limited (TAK) - Yahoo Finance
Search result #6
See Takeda Pharmaceutical Company Limited (TAK) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source

Scenarios

Bull Target (Scenario probability)

$20 / p=20% prob

Base Target (Scenario probability)

$17 / p=60% prob

Bear Target (Scenario probability)

$15 / p=20% prob

Analysis 2026-01-30 · RankAlpha Sentiment AI

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-30
Next quarterly results (assumed window)
Next quarterly earnings release; no firm date published in reviewed sources so a conservative estimate is used (assumed end of window) — market reactions likely to reprice guidance and analyst targets [#SERP-1].
Prob 70.00% • Move 5.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Analyst target revisions
2026-04-30
Analyst target updates following earnings or guidance changes; current scraped targets show a tight median/high range that could be nudged by results or guidance shifts [#SERP-1], [#SERP-3].
Prob 40% • Move 10% • Priced-in 40%

Long-term Catalysts

Months to a year

Pipeline readouts and strategic execution
2027-01-30
Longer-term clinical readouts and portfolio/efficiency execution could materially alter valuation over the next year; timeline conservatively set one year out when specific dates are not publicly disclosed.
Prob 30% • Move 20% • Priced-in 20%

Risks

Failure to deliver integration synergies or cost savings
Major litigation or product-safety event
Material FX (JPY) translation headwinds
Negative clinical readout or regulatory refusal
Pricing/reimbursement pressure limiting launch uptake

Peers

Symbol	Summary
NVS	Diversified, big-pharma peer with sizeable OTC/innovator balance; similar exposure to regulatory and emerging-market dynamics.
PFE	Large U.S.-based peer with heavy vaccine and specialty product exposure; relevant comparator for commercialization and margin comparatives.
SNY	European pharma peer with a broad portfolio and similar exposure to patent cliffs and pipeline risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Takeda Pharmaceutical Co Ltd ADR (TAK) analyst consensus price target high low average
Analysis date: 2026-01-30

Loading AI feed…

Symbol

Summary

NVS

Diversified, big-pharma peer with sizeable OTC/innovator balance; similar exposure to regulatory and emerging-market dynamics.

PFE

Large U.S.-based peer with heavy vaccine and specialty product exposure; relevant comparator for commercialization and margin comparatives.

SNY

European pharma peer with a broad portfolio and similar exposure to patent cliffs and pipeline risk.